Hydralazine reduces myocardial infarct size

Nature Reviews Cardiology, Published online: 18 January 2021; doi:10.1038/s41569-021-00514-7A new study shows that hydralazine, a drug used for the treatment of resistant hypertension and heart failure, can inhibit mitochondrial fission, thereby reducing cardiomyocyte death and myocardial infarct size after ischaemia–reperfusion injury in mice.

Source: Nature Reviews Cardiology - January 18, 2021 Category: Cardiology Authors: Andrew Robson Source Type: research